Del Could Get A Shot In The Arm

Everything seems to be going just dandy for Del Global Technologies (DGTC): It has upped earnings in each of the past 14 years. Its revenues should hit $100 million, up from last year's $68 million. And the Food & Drug Administration has just O.K.'d its new radiographic and fluoroscopic probing device--which will bump up next year's figures. Yet shares of Del, which is a supplier to some of the largest makers of medical imaging systems, including General Electric, Siemens, and Philips, are trading not far from its 52-week low, at 9 a share.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.